Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q86X83
UPID:
COMD2_HUMAN
Alternative names:
-
Alternative UPACC:
Q86X83; Q561V4; Q9H3L5; Q9Y5V1
Background:
COMM domain-containing protein 2 plays a crucial role in cellular processes by potentially modulating the activity of cullin-RING E3 ubiquitin ligase complexes, as evidenced by research findings (PubMed:21778237). Additionally, it may contribute to the down-regulation of NF-kappa-B activation, a key factor in inflammatory and immune responses (PubMed:15799966).
Therapeutic significance:
Understanding the role of COMM domain-containing protein 2 could open doors to potential therapeutic strategies.